▟ Vinebot intrinsic value, daily

← back

IQV IQVIA

pharma · valued with opus medium conviction · deep-dived 2026-11-17

HOLD
Intrinsic value$152.97
Price (at call)$264.73
Margin of safety -42.2%
vs market (rating basis) -1.1%

Data-plus-CRO franchise worth owning, but leverage and full pricing leave little margin of safety.

The story

IQVIA pairs the largest contract research organization with a proprietary real-world healthcare data and analytics franchise, a combination rivals find hard to copy and that makes it the default partner for large pharma. It is a mature compounder: mid-single-digit organic growth with operating leverage. Reported margins are held down by roughly 6 points of amortization from the Quintiles-IMS merger. Revenue reaccelerated to about 6% TTM as the biotech funding slump and trial cancellations eased, though leverage stays high at about $13.7B of net debt.

Growth y1 rises slightly to 6% because TTM revenue grew 6.1% (16.31B to 17.31B). Margin stays near 20% as amortization rolls off and cash-margin economics show through. I made two material moves because my prior value sat more than 50% below a heavily covered price. Sales-to-capital goes from 1.6 to 2.0 because the reported 0.78 is inflated by merger goodwill, while organic growth needs little capital (capex is about 3.8% of revenue). The horizon goes from 8 to 10 years because the data moat and outsourcing penetration give a longer runway than a typical services firm.

Value drivers

Revenue growth (Y1)6.0%
Terminal growth3.0%
Forecast horizon10y
Target operating margin20.0%
Years to target margin5
Sales-to-capital2.00
Beta1.00
Failure probability2.0%
Cost of capital (WACC)9.2%
Terminal WACC9.2%

Valuation bridge

PV of explicit FCFF18.76B
PV of terminal value20.83B
Equity value25.21B
÷ shares → per share$152.97

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 18.35B 6.0% 14.8% 2.29B 519.33M 1.77B 1.62B
2 19.39B 5.7% 16.1% 2.63B 519.91M 2.11B 1.77B
3 20.42B 5.3% 17.4% 2.99B 517.05M 2.47B 1.90B
4 21.44B 5.0% 18.7% 3.37B 510.59M 2.86B 2.01B
5 22.45B 4.7% 20.0% 3.78B 500.38M 3.28B 2.11B
6 23.42B 4.3% 20.0% 3.94B 486.32M 3.46B 2.03B
7 24.35B 4.0% 20.0% 4.10B 468.36M 3.63B 1.96B
8 25.25B 3.7% 20.0% 4.25B 446.51M 3.80B 1.88B
9 26.09B 3.3% 20.0% 4.39B 420.80M 3.97B 1.79B
10 26.87B 3.0% 20.0% 4.52B 391.34M 4.13B 1.71B

Key risks

  • Biotech funding or big-pharma pipeline cuts lead to more trial cancellations and slower bookings
  • High leverage (about $13.7B net debt) makes equity value sensitive to rates and refinancing
  • AI-driven trial design and in-house analytics erode pricing power in the TAS and commercial data segments

Catalysts

  • Book-to-bill sustained above 1.15x, turning backlog into accelerating revenue
  • Acquired-intangible amortization rolls off, lifting GAAP margins toward cash economics, with buybacks shrinking the share count

History

DatePriceIntrinsicMoSRating
2026-11-17$264.73 $152.97 -42.2% HOLD
2026-10-14$260.68 $124.08 -52.4% HOLD
2026-09-10$256.98 $49.45 -80.8% SELL
2026-08-10$238.70 $67.78 -71.6% HOLD
2026-07-07$205.97 $81.43 -60.5% HOLD
2026-06-23$171.28 $83.46 -51.3% HOLD